▲案情简介2006年10月30日,“奥美定”的生产和销售厂家富华公司与国家药监局的撤销医疗器械注册证纠纷案,一审落幕,北京市第一中级人民法院一审判决驳回富华公司的诉讼请求。由于接到许多患者投诉,国家药监局药品评价中心曾对注射用的聚丙烯酰胺水凝胶进行了再评价,认为不能保 ▲ Brief introduction of the case On October 30, 2006, “Ogilvy,” the production and sale of manufacturers Fuhua Company and the State Food and Drug Administration revoked the medical device registration card dispute, first instance ended, Beijing First Intermediate People’s Court rejected the first instance verdict Fuhua company’s claim. Due to complaints from many patients, the CFDA Drug Evaluation Center once again re-evaluated the polyacrylamide hydrogel for injection and concluded that it can not be guaranteed